吉西他滨单药治疗老年晚期非小细胞肺癌临床观察[摘要]目的:观察吉西他滨单药治疗老年晚期非小细胞肺癌(NSCLC)的临床疗效和毒副作用。方法:35例65岁以±NSCLC患者均接受国产吉西他滨(泽菲)800〜1000mg/m2,第1、8天静脉滴注,每21〜28天为1个周期,至少2个周期。结果:35例患者均可评价疗效,其中,完全缓解0例,部分缓解8例,%(8/35)o中位疾病进展时间(TTP),,1年生存率为2&6%。主要毒副作用为白细胞及血小板下降,多为I〜III度,可以耐受。结论:吉西他滨单药治疗老年晚期NSCLC安全有效,不但延长患者的生存时间,且可改善生活质量,毒副作用可以耐受。[关键词]吉西他滨;老年;非小细胞肺癌;化疗[中图分类号][文献标识码]C[文章编号]1673-7210(2009)05(a)-099-02ClinicalobservationofGemcitabinemonotherapyinthetreatmentofelderadvancednon-smallcelllungcancerXIAOJiawen,SUNSuhua(DepartmentofOncology,theFifthPeople"sHospitalofShenyang,Shenyemgl10023,China)[Abstract]Objective:ToobservetheclinicalefficacyandtoxicityofGemcitabinemonotherapyinthetreatmentofelderadvancednon-smallcelllungcancer(NSCLC)・Methods:35patientsagedover65withadvancednon-smallcelllungcancerreceivedGemcitabine800〜1000mg/m2ondl,〜:Inthe35evaluablecasesORwasobservedin0caseandPR8cases,%(8/35),Mediantimetoprogression(TTP),%.Themaintoxicitieswereleucopeniaandthrombocytopenia,・Conclusion: Gemcitabinemonotherapy iseffectiveandsafeinthetreatmentofelderadvancedNSCLC・ItprolongthesurvivaltimeandimprovethequalityoflifeinpatientswithNSCLC・Thetoxicititswerewelltolerated・[Keywords]Gemci
吉西他滨单药治疗老年晚期非小细胞肺癌临床观察 来自淘豆网m.daumloan.com转载请标明出处.
